Comparative Pharmacology
Head-to-head clinical analysis: DIUCARDIN versus FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIUCARDIN versus FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE.
DIUCARDIN vs FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.
Fosinopril is an ACE inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Hydrochlorothiazide 25-50 mg orally once daily, titrated based on response. Maximum dose 100 mg/day.
1 tablet (fosinopril 10 mg/hydrochlorothiazide 12.5 mg or fosinopril 20 mg/hydrochlorothiazide 12.5 mg) orally once daily. Maximum dose: fosinopril 80 mg/hydrochlorothiazide 50 mg per day.
None Documented
None Documented
Terminal elimination half-life is approximately 18-24 hours in normal renal function. This prolongs significantly in renal impairment, requiring dose adjustment.
Fosinoprilat: 11.5 h (terminal); Hydrochlorothiazide: 6-15 h (biphasic, terminal phase 10-15 h).
Primarily renal excretion: approximately 60-70% of the dose is excreted unchanged in urine within 24 hours. Biliary/fecal elimination accounts for about 20-30%, with some enterohepatic circulation.
Fosinopril: 45% renal, 55% biliary/fecal; Hydrochlorothiazide: >95% renal (unchanged).
Category C
Category A/B
Thiazide Diuretic
Thiazide Diuretic